FIELD: medicine, pharmaceutics.
SUBSTANCE: in the general formula (I), R1 is specified in cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each of which can be substituted by (1-4C)alkyl, phenyl, biphenyl, naphthyl each of which can be substituted by three substitutes independently specified in halogen, (1-4C)alkyl substituted as may be necessary by one or more atoms of fluorine, (2-4C)alkynyl, (1-4C)alkoxy substituted as may be necessary by one or more atoms of fluorine, amino, di(1-4C)alkylamino and (3-6C)cycloalkyl, phenyl substituted by phenoxy, benzyl, benzyloxy, phenylethyl or a monocyclic heterocycle, each of which can be substituted by (1-4C)alkyl, 5-6-merous monocyclic heterocycle containing 1-3 heteroatoms specified in N, O and S substituted as may be necessary by a halogen, (1-4C)alkyl or phenyl substituted as may be necessary by (1-4C)alkyl, and 9-10-merous bicyclic heterocycle containing 1-2 heteroatoms specified in N and O substituted as may be necessary by (1-4C)alkyl; A is specified in -CO-O-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and a binding group -Y-(CH2)n-X-, wherein Y is attached to R1 and specified in a bond, -O-, -SO2-, -CH2-O-, -CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C- and -C≡C-; n means an integer from 1 to 7; and X is attached to a phenylene group and specified in a bond, -O-, -S-, and -NH; the ring structure B represents phenylene; R2 means H, (1-4C)alkyl substituted as may be necessary by one or more atoms of fluorine, (1-4C)alkoxy or halogen; and R3 means (1-4C)alkylene-R5, wherein the alkylene group can be substituted by one or more atoms of a halogen, or R3 means (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 means -OH, -PO3H2, -OPO3H2, -COOH or tetrazol-5-yl; R4 means H or (1-4C)alkyl; R6 means one or more substitutes independently specified in H, (1-4C)alkyl or oxo; W means -O- or -S-.
EFFECT: invention refers to (thio)morpholine derivatives of formula (I) possessing the property of a sphingosine-1-phosphate (S1P) modulator, a based pharmaceutical composition and using them.
18 cl, 1 dwg, 237 ex
Title | Year | Author | Number |
---|---|---|---|
SPIROCYCLIC AMINE DERIVATIVES AS S1P MODULATORS | 2011 |
|
RU2602800C2 |
SUBSTITUTED PYRAZOLES | 2001 |
|
RU2286343C2 |
SUBSTITUTED MORPHOLINES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF COUNTERACTION TO SUBSTANCE P OR INHIBITION OF NEUROKININ-1 RECEPTORS | 1995 |
|
RU2170233C2 |
METHOD FOR TREATMENT ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2277909C2 |
NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND USE THEREOF IN INCREASING ENDOGENOUS ERYTHROPOIETIN | 2004 |
|
RU2379291C2 |
AROMATIC 6,7-DISUBSTITUTED 3-QUINOLINECARBOXAMIDE DERIVATIVES, METHOD FOR PRODUCTION THEREOF (VARIANTS), PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND USE THEREOF IN DRUG MANUFACTURING | 2002 |
|
RU2281940C2 |
DERIVATIVES OF PYRIMIDINE, PHARMACEUTICAL COMPOSITION AND METHOD OF PROPHYLAXIS AND TREATMENT OF DISEASE | 1996 |
|
RU2170734C2 |
ARYLCARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | 2003 |
|
RU2340605C2 |
NITROGEN-CONTAINING HETEROARYL DERIVATIVES | 2004 |
|
RU2375350C2 |
ARYLMETHOXY ISOINDOLIN DERIVATIVE, COMPOSITIONS INCLUDING THEREOF AND METHODS OF THEIR APPLICATION | 2011 |
|
RU2567753C2 |
Authors
Dates
2015-07-20—Published
2010-08-27—Filed